A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

被引：552

作者：

Bekker, PJ

Holloway, DL

Rasmussen, AS

Murphy, R

Martin, SW

Leese, PT

Holmes, GB

Dunstan, CR

DePaoli, AM

机构：

[1] Amgen Inc, Thousand Oaks, CA 91320 USA

[2] Quintiles, Lenexa, KS USA

[3] SFBC Int Inc, Miami, FL USA

[4] ANZAC Res Inst, Concord, NSW, Australia

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2004年 / 19卷 / 07期

关键词：

RANKL; osteoprotegerin; osteoporosis; bone resorption; AMG; 162;

D O I：

10.1359/JBMR.040305

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The safety and bone antiresorptive effect of a single subcutaneous dose of AMG 162, a human monoclonal antibody to RANKL, was investigated in 49 postmenopausal women. AMG 162 is a potent antiresorptive agent for diseases such as osteoporosis.

引用

页码：1059 / 1066

页数：8

共 50 条

[21] Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint [J].

Haynes, DR ;

Crotti, TN ;

Loric, M ;

Bain, GI ;

Atkins, GJ ;

Findlay, DM .

RHEUMATOLOGY, 2001, 40 (06) :623-630

[22] The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis [J].

Haynes, DR ;

Crotti, TN ;

Potter, AE ;

Loric, M ;

Atkins, GJ ;

Howie, DW ;

Findlay, DM .

JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 2001, 83B (06) :902-911

[23] Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord [J].

Honore, P ;

Luger, NM ;

Sabino, MAC ;

Schwei, MJ ;

Rogers, SD ;

Mach, DB ;

O'Keefe, PF ;

Ramnaraine, ML ;

Clohisy, DR ;

Mantyh, PW .

NATURE MEDICINE, 2000, 6 (05) :521-528

[24] Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis [J].

Hughes, AE ;

Ralston, SH ;

Marken, J ;

Bell, C ;

MacPherson, H ;

Wallace, RGH ;

van Hul, W ;

Whyte, MP ;

Nakatsuka, K ;

Hovy, L ;

Anderson, DM .

NATURE GENETICS, 2000, 24 (01) :45-48

[25] Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women -: Three-year data from 2 double-blind, randomized, placebo-controlled trials [J].

Johnston, CC ;

Bjarnason, NH ;

Cohen, FJ ;

Shah, A ;

Lindsay, R ;

Mitlak, BH ;

Huster, W ;

Draper, MW ;

Harper, KD ;

Heath, H ;

Gennari, C ;

Christiansen, C ;

Arnaud, CD ;

Delmas, PD .

ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (22) :3444-3450

[26]

Ju HSJ, 1997, CLIN CHEM, V43, P1570

[27] RANK ligand is a prerequisite for cancer-associated osteolytic lesions [J].

Kitazawa, S ;

Kitazawa, R .

JOURNAL OF PATHOLOGY, 2002, 198 (02) :228-236

[28] Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand [J].

Kong, YY ;

Feïge, U ;

Sarosi, I ;

Bolon, B ;

Tafuri, A ;

Morony, S ;

Capparelli, C ;

Li, J ;

Elliott, R ;

McCabe, S ;

Wong, T ;

Campagnuolo, G ;

Moran, E ;

Bogoch, ER ;

Van, G ;

Nguyen, LT ;

Ohashi, PS ;

Lacey, DL ;

Fish, E ;

Boyle, WJ ;

Penninger, JM .

NATURE, 1999, 402 (6759) :304-309

[29] OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis [J].

Kong, YY ;

Yoshida, H ;

Sarosi, I ;

Tan, HL ;

Timms, E ;

Capparelli, C ;

Morony, S ;

Oliveira-dos-Santos, AJ ;

Van, G ;

Itie, A ;

Khoo, W ;

Wakeham, A ;

Dunstan, CR ;

Lacey, DL ;

Mak, TW ;

Boyle, WJ ;

Penninger, JM .

NATURE, 1999, 397 (6717) :315-323

[30] OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats [J].

Kostenuik, PJ ;

Capparelli, C ;

Morony, S ;

Adamu, S ;

Shimamoto, G ;

Shen, V ;

Lacey, DL ;

Dunstan, CR .

ENDOCRINOLOGY, 2001, 142 (10) :4295-4304

← 1 2 3 4 5 →